Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Last updated: March 17, 2026
Sponsor: Boehringer Ingelheim
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

N/A

Treatment

JARDIANCE®

Clinical Study ID

NCT06527846
1245-0340
  • All Genders

Study Summary

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with CKD who are prescribed JARDIANCE® Tablets for CKD according to thecurrent Japanese package insert and who provided written informed consent prior toenrolment in this study.

  • Patients who have never been treated with JARDIANCE® Tablets (including treatmentfor Type 2 diabetes mellitus (T2DM) and/or chronic heart failure (CHF)) beforeenrolment.

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 1024
Treatment Group(s): 1
Primary Treatment: JARDIANCE®
Phase:
Study Start date:
October 22, 2024
Estimated Completion Date:
March 31, 2027

Connect with a study center

  • Nippon Boehringer Ingelheim Co., Ltd.

    Tokyo, 1416017
    Japan

    Site Not Available

  • Nippon Boehringer Ingelheim Co., Ltd.

    Tokyo 1850147, 1416017
    Japan

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.